Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer

After the introduction of trastuzumab, a monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2), the overall survival (OS) among patients with HER2-positive breast cancer has been substantially improved. However, among these patients, the incidence of brain metastases (BM)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Peng, Gao, Song-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2017
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627687/
https://www.ncbi.nlm.nih.gov/pubmed/29063053
http://dx.doi.org/10.1016/j.cdtm.2017.01.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627687/
https://www.ncbi.nlm.nih.gov/pubmed/29063053
http://dx.doi.org/10.1016/j.cdtm.2017.01.004

Ejemplares similares